Clinical evolution of patients with rheumatoid arthritis high and moderate activity treated bDMARDS, measure DAS28. Fundacion Investigación Médica del Atlantico
DOI:
https://doi.org/10.18041/2390-0512/bioc..2.2633Keywords:
Rheumatoid arthritis, bDMARDS, DAS28Abstract
Objective: Determine clinical evolution of patients with rheumatoid arthritis high and moderate activity treated bDMARDS, measure DAS28. Fundacion Investigacion Medica del Atlantico, period January-May 2015. Materials and Methods: Ambispective descriptive study, in 39 patients diagnosed with rheumatoid arthritis previously treated with methotrexate (MTX) and began bDMARDS with high and moderate activity by DAS28, set controls (3, 6, 9 and 12 months) were performed.
Results: Sex distribution showed more frequent in females with 84.6 %; the mean age was 51.4 ± 16.0 years; the mean time of diagnosis 7.1 ± 5.2 years; 100 % of patients admitted with moderate and high activity (DAS28), after 12 months of treatment low activity was observed in 33.3 % moderate activity in 56.4 % and high activity at 10.3 %.
Conclusions: Patients treated with bDMARDS exhibit satisfactory clinical outcome, significantly improving functional capacity, the structural damage and the quality of life of these patients
Downloads
References
2. Zeidler H. The need to better classify and diagnose early and very early rheumatoid arthritis. J Rheumatol. 2012; 39(2):212-7.
3. Anaya JM, Pineda-Tamayo R, Gómez LM, Galarza Maldonado C, Rojas-Villaraga A, Martin J. Artritis reumatoide: bases moleculares, clínicas y terapéuticas. Medellín: CIB, Universidad del Rosario, FUNPAR; 2006.
4. Cardiel, MH, Rojas-Serrano J. Community based study to estimate prevalence, burden of illness and help seeking behavior in rheumatic
diseases in Mexico City. A COPCORD study. Clin Exp Rheumatol. 2002; 20(5):617-24.
5. Weiss JE, Ilowite N. Juvenile Idiopatic Arthritis. Rheum Dis Clin Am. 2007; 33(4):441-70.
6. Silman AJ, Hochberg MC. Epidemiology of the rheumatic diseases. 2nd ed. Oxford: Oxford University Press; 2001.
7. Ravelli A and Martini A. Juvenile idiopathic arthritis. Lancet. 2007; 369(9563):767-78.
8. Pugner KM, Scott DI, Holmes JW, Hieke K. The Cost of Rheumatoid Arthritis: An International Long-term View. Semin Arthritis Rheum.
2000; 29:305-20.
9. Rueda J, González H, Abello-Banfi M. Evaluación y seguimiento de pacientes con artritis reumatoide. Colombia: Edimeco S A; 1998.
10. Han C, Smolen J, Kavanaugh A, St.Clair EW, Baker D, Bala M. Comparison of employability outcomes among patients with early or
long-standing rheumatoid arthritis. Arthritis Rheum. 2008; 59:510-4.
11. Caballero C, Chalem P, Londoño J, Restrepo J, Iglesias A, Sánchez P, et al, Primer consenso colombiano sobre el tratamiento de la artritis
reumatoide temprana. Revista Colombiana de Reumatología. 2002; 9(2):323-331.
12. Callhoff J, Weib A, Zink A, and Listing J. Impact of biologic therapy on functional status in patients with rheumatoid arthritis-a metaanalysis.
Rheumatology. 2013; 52:2127-35.
13. Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, et al. American College of Rheumatology 2008 recommendations for
the use of nonbiologic and biologic diseasemodifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 2008; 59:762-84.
14. Neogi T, Aletaha D, Silman A, Naden RL, Felson DT, Aggarwal R, et al. The 2010 American College of Rheumatology/European League
Against Rheumatism classification criteria for rheumatoid arthritis: Phase 2 methodological report. Arthritis & Rheumatism. 2010; 62(9):2582-91.
15. Singh JA, Noorbaloochi S, Singh G. Golimumab for rheumatoid arthritis. Cochrane Database Syst Rev. 2010; 1:83-4.
16. PRESERVE STUDY. Mantenimiento, reducción o retirada de etanercept después del tratamiento con etanercept y metotrexato en
pacientes con artritis reumatoide moderada: ensayo controlado aleatorio. The Lancet. 2013; 381(9870):918-929.
17. Anaya JM, Correa PA, Mantilla RD, ArcosBurgos M. Rheumatoid arthritis association in Colombian population is restricted to HLADRB1* 04 QRRAA alletes. Genes and Immunity. 2002; 3:56-8.
18. Díaz J, Brenes F. Eficacia de los agentes antiTNFα en una cohorte de pacientes con artritis reumatoide en Costa Rica. Rev. Colomb. Reumatol. 2010; (17)4:205-11.
19. Marnell L, Mold C, Du Clos TW. C-reactive protein: ligands, receptors and role in inflammation. Clin Immunol. 2005; 117:104-11.
Downloads
Published
Issue
Section
License
-
Reconocimiento — Debe reconocer adecuadamente la autoría, proporcionar un enlace a la licencia e indicar si se han realizado cambios<. Puede hacerlo de cualquier manera razonable, pero no de una manera que sugiera que tiene el apoyo del licenciador o lo recibe por el uso que hace.
-
NoComercial — No puede utilizar el material para una finalidad comercial.
-
CompartirIgual — Si remezcla, transforma o crea a partir del material, deberá difundir sus contribuciones bajo la misma licencia que el original.
- No hay restricciones adicionales — No puede aplicar términos legales o medidas tecnológicas que legalmente restrinjan realizar aquello que la licencia permite.
